{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.4","upperLimit":"2.8","value":"1.41"},{"groupId":"OG001","lowerLimit":"2.3","upperLimit":"4.0","value":"3.15"},{"groupId":"OG002","lowerLimit":"1.3","upperLimit":"2.7","value":"1.99"},{"groupId":"OG003","lowerLimit":"1.3","upperLimit":"6.8","value":"2.73"},{"groupId":"OG004","lowerLimit":"2.6","upperLimit":"5.7","value":"3.63"},{"groupId":"OG005","lowerLimit":"1.2","upperLimit":"7.0","value":"2.78"},{"groupId":"OG006","lowerLimit":"1.2","upperLimit":"6.8","value":"1.38"},{"groupId":"OG007","lowerLimit":"1.9","upperLimit":"5.7","value":"3.50"},{"groupId":"OG008","lowerLimit":"1.9","upperLimit":"5.5","value":"2.81"},{"groupId":"OG009","lowerLimit":"1.1","upperLimit":"12.8","value":"2.00"},{"groupId":"OG010","lowerLimit":"1.2","upperLimit":"5.5","value":"2.58"},{"groupId":"OG011","lowerLimit":"1.2","upperLimit":"8.7","value":"2.66"},{"groupId":"OG012","lowerLimit":"1.4","upperLimit":"4.2","value":"2.66"},{"groupId":"OG013","lowerLimit":"1.3","upperLimit":"5.7","value":"5.13"},{"groupId":"OG014","lowerLimit":"1.3","upperLimit":"8.1","value":"4.17"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"11"},{"groupId":"OG004","value":"8"},{"groupId":"OG005","value":"10"},{"groupId":"OG006","value":"7"},{"groupId":"OG007","value":"8"},{"groupId":"OG008","value":"4"},{"groupId":"OG009","value":"16"},{"groupId":"OG010","value":"16"},{"groupId":"OG011","value":"15"},{"groupId":"OG012","value":"3"},{"groupId":"OG013","value":"5"},{"groupId":"OG014","value":"10"}],"units":"Participants"}],"description":"Time to Response (TTR) defined as the time from randomization to the date of the first confirmed CR or PR for Cohort 3, 4 and 6, and from the first dosing date of study medication to the date of the first confirmed CR or PR for cohort 1, 2 and 5.\n\nComplete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\< 10 mm.\n\nPartial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.","dispersionType":"Full Range","groups":[{"description":"Dose Escalation: Uninfected hepatocellular carcinoma (HCC) participants received nivolumab 0.1/0.3/1/3/10 mg/kg every 2 weeks","id":"OG000","title":"Cohort 1 Uninfected HCC"},{"description":"Dose Escalation: Hepatitis C (HCV)-infected participants received nivolumab 0.3/1/3 mg/kg every 2 weeks","id":"OG001","title":"Cohort 1 HCV Infected"},{"description":"Dose Escalation: Hepatitis B (HBV)-infected participants received nivolumab 0.1/0.3/1/3 mg/kg every 2 weeks","id":"OG002","title":"Cohort 1 HBV Infected"},{"description":"Dose Expansion: Uninfected hepatocellular carcinoma (HCC) participants who are sorafenib naive/intolerant received nivolumab 3 mg/kg every 2 weeks","id":"OG003","title":"Cohort 2 Uninfected Sorafenib Naive/Intolerant: Treatment 1"},{"description":"Dose Expansion: Uninfected hepatocellular carcinoma (HCC) participants who are sorafenib progressors received nivolumab 3 mg/kg every 2 weeks","id":"OG004","title":"Cohort 2 Uninfected Sorafenib Progressors: Treatment 2"},{"description":"Dose Expansion: Hepatitis C (HCV)-infected participants received nivolumab 3 mg/kg every 2 weeks","id":"OG005","title":"Cohort 2 HCV Infected: Treatment 3"},{"description":"Dose Expansion: Hepatitis B (HBV)-infected participants received nivolumab 3 mg/kg every 2 weeks","id":"OG006","title":"Cohort 2 HBV Infected: Treatment 4"},{"description":"Arm A: Advance hepatocellular carcinoma (HCC) participants received nivolumab 240 mg every 2 weeks","id":"OG007","title":"Cohort 3: Treatment 1"},{"description":"Arm B: Advance hepatocellular carcinoma (HCC) participants received Sorafenib 400 mg twice a day","id":"OG008","title":"Cohort 3: Treatment 2"},{"description":"Arm A: Participants received nivolumab 1 mg/kg + ipilimumab 3 mg/kg every 3 weeks","id":"OG009","title":"Cohort 4: Treatment 1"},{"description":"Arm B: Participants received nivolumab 3 mg/kg + ipilimumab 1 mg/kg every 3 weeks","id":"OG010","title":"Cohort 4: Treatment 2"},{"description":"Arm C: Participants received nivolumab 3 mg/kg every 2 weeks + ipilimumab 1 mg/kg every 6 weeks","id":"OG011","title":"Cohort 4: Treatment 3"},{"description":"Participants received nivolumab 240 mg every 2 weeks","id":"OG012","title":"Cohort 5: Treatment 1"},{"description":"Participants received nivolumab 240 mg every 2 weeks + cabozantinib 40 mg once daily","id":"OG013","title":"Cohort 6: Treatment 1"},{"description":"Participants received nivolumab 3 mg/kg every 2 weeks + ipilimumab 1 mg/kg every 6 weeks + cabozantinib 40 mg once daily","id":"OG014","title":"Cohort 6: Treatment 2"}],"paramType":"MEDIAN","populationDescription":"All treated participants for Cohort 1, 2, and 5, and all randomized participants for Cohort 3, 4 and 6 whose best overall response (BOR) is either complete response (CR) or partial response (PR). Uninfected HCC, HCV-infected, and HBV-infected participants were pre-specified to be reported together for Cohort 1.","reportingStatus":"POSTED","timeFrame":"From the date of randomization (Cohort 3, 4, 6) or the date of first dose (Cohort 1, 2, 5) to the date of attainment of complete response (CR) or partial response (PR) (up to approximately 144 months)","title":"Time to Response (TTR) Assessed by Blinded Independent Central Review (BICR)","type":"SECONDARY","unitOfMeasure":"Months"}